Atsushi Tatsuguchi

Dr. Atsushi Tatsuguchi

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2009 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
TSTsuguhiko Seo
Tsuguhiko Seo
ATAtsushi Tatsuguchi
Atsushi Tatsuguchi
SSSeiichi Shinji
Seiichi Shinji
MYMasaoki Yonezawa
Masaoki Yonezawa
KMKeigo Mitsui
Keigo Mitsui
CSChoitsu Sakamoto
Choitsu Sakamoto

22 November 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
KMKeigo Mitsui
Keigo Mitsui
MYMasaoki Yonezawa
Masaoki Yonezawa
ATAtsushi Tatsuguchi
Atsushi Tatsuguchi
Seiichi ShinjiSeiichi Shinji
Seiichi Shinji
KGKatya Gudis
Katya Gudis
CSChoitsu Sakamoto
Choitsu Sakamoto
The ErbB family consists of four proteins including (EGFR)/ErbB1, ErbB2, ErbB3, and ErbB4, and plays a crucial role in the promotion of multiple tumorigenic processes. In addition to the traditional pathways of EGFR signaling, EGFR translocates to the nucleus and acts as a transcription factor in the proliferation of cancer cells. Heregulin is known as both an ErbB3 and an ErbB4 ligand. This study aimed to investigate the expression of heregulin and its relevant EGFR family members as well as their phosphorylated forms in human colorectal cancer (CRC) tissues and to determine the relationship between their expression and clinicopathological factors including patient prognosis. We analyzed the effects of exogenous heregulin on ErbB2, ErbB3 and ErbB4 phosphorylation in Caco-2, DLD-1, and HCT 116 colon cancer cell lines by western blot analysis. We examined 155 surgical resections from colorectomy patients. Cellular localization of ErbB1-4, their phosphorylated forms and heregulin protein was analyzed in CRC surgical resections by immunohistochemical analysis. Immunohistochemical results were compared with clinicopathological factors and patient prognosis. Phosphorylated ErbB2 (pErbB2) and phosphorylated ErbB3 (pErbB3) were detected in both nuclear and cytosolic fractions of Caco-2 and DLD-1 cells stimulated by exogenous heregulin. Whereas, phosphorylated ErbB4 (pErbB4) was detected only in cytosolic fractions of HCT 116 cells stimulated by exogenous heregulin. Phosphorylated EGFR (pEGFR) immunoreactivity was observed in the cytoplasm and nuclei of cancer cells, whereas the pattern of EGFR staining was membranous and cytoplasmic. Subcellular localization of pErbB2, cytoplasmic, membranous, or nuclear, varied among cases. pErbB3 immunoreactivity was exclusively observed in the nuclei of cancer cells. pErbB4 immunoreactivity was observed in the cell membrane of cancer cells. Statistically, heregulin immunoreactivity correlated with pErbB2 and pErbB4 expression. In multivariate analysis for disease free survival, lymph node status, pErbB3 and pErbB4 expression retained independent prognostic significance. In multivariate analysis for overall survival, lymph node status, pEGFR and pErbB4 retained independent prognostic significance. ErbB2 and ErbB3 phosphorylated by heregulin localized in the nucleus of CRC cells. Phosphorylated ErbB1-4 and heregulin contribute to poorer patient prognosis in CRC. This heregulin-ErbB family member autocrine loop may be a candidate for targeted treatment of CRC.

14 September 2007 in Human Pathology
Verified
Journal Article
Closed access
KGKatya Gudis
Katya Gudis
ATAtsushi Tatsuguchi
Atsushi Tatsuguchi
KWKen Wada
Ken Wada
THTetsuro Hiratsuka
Tetsuro Hiratsuka
SFSeiji Futagami
Seiji Futagami
CSChoitsu Sakamoto
Choitsu Sakamoto

1 October 2020 in Pathology - Research and Practice
Verified
Journal Article
Open access
ATAtsushi Tatsuguchi
Atsushi Tatsuguchi
SHShintaro Hoshino
Shintaro Hoshino
NKNoriyuki Kawami
Noriyuki Kawami
KGKatya Gudis
Katya Gudis
TNTsutomu Nomura
Tsutomu Nomura
KIKatsuhiko Iwakiri
Katsuhiko Iwakiri
Proton pump inhibitor (PPI) therapy causes hypergastrinemia, which could promote the development and progression of neuroendocrine tumors (NETs). Concerns have been raised about the safety of long-term PPI use due to a possible increased risk of NETs. This study aimed to investigate the association between hypergastrinemia and the risk of NETs. Twenty outpatients presenting with serum gastrin levels greater than 400 pg/mL after long-term PPI treatment were registered in this study. Immunohistochemical analyses for chromogranin A (CgA), Ki67, gastrin and CCK/B gastrin receptor (CCKBR) were performed, and positive cell numbers were counted. There were no NET or gastric epithelial neoplasia cases observed among any of the 20 patients examined throughout the PPI treatment period. Histologically, ECL cell hyperplasia were shown in all patients. However, no relationship was found between serum gastrin levels and the number of CgA positive ECL cells. There was also no relationship between serum gastrin levels and the proportion of Ki67 positive cells or the density of CCKBR positive cells. The data indicate no relationship may exist between NETs and hypergastrinemia secondary to PPI treatment in patients having no, or mild, atrophic gastritis.

1 January 1997 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
TKT. Kishida
T. Kishida
ISI. Shinozawa
I. Shinozawa
STShu Tanaka
Shu Tanaka
THT. Hoshino
T. Hoshino
ATAtsushi Tatsuguchi
Atsushi Tatsuguchi
MKM. Kobayashi
M. Kobayashi
Background: Colorectal adenomas are often detected on mass screening, although detection rates with fecal occult blood tests are low. The relationship between colorectal adenomas and the resulting blood loss was examined indirectly, using serum iron and ferritin levels. Methods: Serum iron and ferritin concentrations were measured in 184 men with colorectal adenomas (±1cm in 92; < 1 cm in 92) and in 92 healthy male controls. Values in the three groups were compared. In the patients with adenomas ≫1 cm, serum iron and ferritin levels were compared on the basis of the site, number, histology, and degree of dysplasia of the adenoma. Results: The mean serum iron level was significantly lower in patients with adenomas ≫1 cm than in controls (P < 0.05), although this level did not differ significantly between those with adenomas < 1 cm and controls. The mean serum ferritin level also was significantly lower in patients with adenomas ≫1 cm than in those with adenomas < 1 cm and controls (P < 0.05, P < 0.01, respectively), although this level did not differ between those with adenomas < 1 cm and controls. There was no difference in mean serum iron or ferritin levels on the basis of the site, number, histology, or degree of dysplasia of the adenoma. Conclusions: We conclude that decreased serum iron and ferritin levels are related only to adenoma size and that adenomas ≫1 cm may bleed steadily, resulting in iron deficiency. However, low dietary intake of iron and fiber may be one of the causes of low serum iron and ferritin.

2 July 2022 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ATAtsushi Tatsuguchi
Atsushi Tatsuguchi
TYTakeshi Yamada
Takeshi Yamada
KUKoji Ueda
Koji Ueda
HFHiroyasu Furuki
Hiroyasu Furuki
AHAitoshi Hoshimoto
Aitoshi Hoshimoto
KIKatsuhiko Iwakiri
Katsuhiko Iwakiri
Background: Small bowel adenocarcinomas (SBAs) are rare and there is little comprehensive data on SBA genomic alterations for Asian patients. This study aimed to profile genomic alterations of SBA in Japanese patients using targeted next-generation sequencing (NGS). Methods: We examined 22 surgical resections from patients with primary SBA. SBA genomic alterations were analyzed by NGS. Mismatch repair (MMR) status was determined by immunohistochemical analysis. Mucin phenotypes were classified as gastric (G), intestinal (I), gastrointestinal (GI), and null (N) types on MUC2, MUC5AC, MUC6, and CD10 immunostaining. Results: The most common genomic alterations found in SBA tumors were TP53 (n = 16), followed by KRAS (n = 6), APC (n = 5), PIK3CA (n = 4), CTNNB1 (n = 3), KIT (n = 2), BRAF (n = 2), CDKN2A (n = 2), and PTEN (n = 2). Deficient MMR tumors were observed in 6 out of 22 patients. Tumor mucin phenotypes included 2 in G-type, 12 in I-type, 3 in GI-type, and 5 in N-type. APC and CTNNB1 mutations were not found in G-type and GI-type tumors. KRAS mutations were found in all tumor types except for G-type tumors. TP53 mutations were found in all tumor types. Although no single gene mutation was associated with overall survival (OS), we found that KRAS mutations were associated with significant worse OS in patients with proficient MMR tumors. Conclusions: SBA genomic alterations in Japanese patients do not differ significantly from those reports in Western countries. Tumor localization, mucin phenotype, and MMR status all appear to impact SBA gene mutations.